液體栓塞系統市場：現況分析與預測（2023-2030）

由於不健康的生活方式導致全球免疫缺陷的盛行率不斷增加，液體栓塞系統市場預計將穩定成長1.5%左右。 例如，根據BMC Public Health 的數據，2023 年7 月，不健康生活方式的盛行率分別為86.4% 的飲食、14.5% 的酒精、6.0% 的菸草、72.2% 的體力活動、42.3% 的螢幕時間和63.9% 的睡眠時間。 此外，根據 2021 年全國藥物使用與健康調查 (NSDUH)，2020 年 12 歲及以上的人有 2,950 萬人患有酒精使用障礙 (AUD)。 其他幾個因素正在推動全球對液體栓塞系統的需求，包括遺傳疾病的增加。 除此之外，利用先進治療劑加速診斷測試，從而加快治療程序並提高準確性，正在穩步推動液體栓塞系統市場的發展。 如今，公司正努力提供環保產品。 例如，Medtronic的Onyx 34L LES 6ml小瓶包裝由98%可回收材料製成，使其成為環保產品。

依類型劃分，市場分為液體栓塞瓶和液體栓塞預填充注射劑。 在2022年全球液體栓塞系統市場中，液體栓塞瓶細分市場佔據最大份額。 該細分市場佔據市場主導地位的原因是使用該產品進行大容量處理的高度可行性。 由於需要較少的儲存空間而易於使用也是該細分市場的一個驅動因素。 因此，液體栓塞瓶將在2022年的刀片型市場中佔據很大份額。

依適應症，市場分為腦動靜脈畸形、腫瘤/腦腫瘤、腦動脈瘤等。 由於腦動靜脈畸形病例和遺傳異常的數量不斷增加，預計在預測期內，腦動靜脈畸形細分市場將佔據相當大的市場份額。 例如，根據腦動脈瘤基金會的統計，約5%至10%的患者在常規檢查中發現動靜脈畸形，但約一半的患者由於突然出血或中風而導致動靜脈畸形的存在變得明顯。它成為了 因此，預計腦動靜脈畸形類別在預測期內將表現出較高的複合年增長率。

依最終用戶劃分，市場分為醫院、門診手術中心等。 醫院類別是根據醫院提供的醫療保健的可及性、高素質的醫療人員的可用性、先進的醫療技術的使用以及世界各地的單位數量的多樣化而按醫院分類的。2022 年。 例如，根據美國醫院協會2023年的數據，2022年美國共有6,129家醫院，擁有919,649張臨床床位和34,011,386名住院病患。 醫院領域的市場競爭非常激烈，預計這種情況在可預見的未來仍將持續。 因此，2022年的市場規模將由醫院產業主導。

為了更了解液態栓塞系統的市場介紹，市場包括北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利、歐洲其他地區）、亞太地區（中國、日本、印度、世界其他地區（亞太）和世界其他地區。 預計在預測期內，亞太地區全球液體栓塞系統市場將以高複合年增長率成長。 在預測期內，有幾個因素正在推動市場成長，例如開放廣泛的醫療產品、增加可及性、慢性病患者數量的增加以及醫療保健支出的多樣化。 例如，根據美國國立衛生研究院的數據，2022年中國新增癌症患者數約為482萬人和237萬人。 此外，該地區主要醫療器材公司的存在、政府措施和特殊社區的擴散也對市場成長產生正面影響。 該地區在婦女健康檢查方面取得了顯著的進展和加強。 因此，從地區來看，預計亞太地區在預測期內將呈現更高的複合年增長率。

目錄

第一章市場介紹

• 市場定義
• 主要目標
• 利害關係人
• 限制

第二章研究方法或假設

• 調查過程
• 調查方法
• 受訪者簡介

第三章市場總結

第 4 章執行摘要

第五章 COVID-19 對液體栓塞系統市場的影響

第六章液體栓塞系統市場收入（2020-2030）

第 7 章按類型劃分的市場洞察

• 液態栓塞瓶
• 液態栓塞預充註註射液

第 8 章依指標劃分的市場洞察

• 腦動靜脈畸形
• 腫瘤與腦腫瘤
• 腦動脈瘤
• 其他

第 9 章最終使用者的市場洞察

• 醫院
• 門診手術中心
• 其他

第 10 章按地區劃分的市場洞察

• 北美
  • 美國
  • 加拿大
  • 北美其他地區
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 亞太地區其他地區
• 世界其他地區

第十一章液體栓塞系統市場動態

• 市場驅動因素
• 市場挑戰
• 影響分析

第十二章液體栓塞系統市場機會

第十三章液體栓塞系統市場趨勢

第14章需求面與供給面分析

• 需求方分析
• 供給面分析

第 15 章價值鏈分析

第16章競爭場景

• 競爭狀況
  • 波特五力分析

第十七章公司簡介

• Medtronic
• Terumo Corporation
• BALT group
• Johnson & Johnson Services, Inc.
• Meril Life Sciences Pvt. Ltd.
• Fluidx Medical Technology, Inc.
• Instylla, Inc.
• TheraTarget
• Sirtex SIR-Spheres Pty Ltd.
• NeuroSafe Medical Co., Ltd.

第十八章免責聲明

A liquid embolic system is a medical device used in healthcare services for the treatment of blood vessel abnormalities, including aneurysms, AVMs, tumors, etc. to prevent severe bleeding in blood vessels. These agents are available in the form of vials and injections and delivered into the vascular malformation sites using a catheter guided by X-ray imaging. Factors such as rising demand for minimally invasive procedures, rising cancer cases, and genetic disorders provide a propelling force to the liquid embolic system market. For instance, as per the Centers for Disease Control and Prevention, in the U.S., increasing age poses a high risk of developing gynecological cancers in most women. It has been estimated that each year in the U.S., about 71,500 new cases of gynecological cancers are diagnosed, including cervical, ovarian, uterine, vaginal, and vulvar cancers. Several factors, including a surge in diagnostic tests, a growing number of obese people, increasing awareness regarding chronic diseases like cancer, rising cancer screening programs, unhealthy lifestyles, and increased investments from the government, public, and private sectors in oncology departments are driving the growth of the market during the forecast period.

The Liquid Embolic System Market is expected to grow at a steady rate of around 1.5% owing to the increased prevalence of immune system deficiency globally due to unhealthy lifestyles. For instance, according to the BMC Public Health, in July 2023, the prevalence of unhealthy lifestyles was 86.4% for diet, 14.5% for alcohol, 6.0% for tobacco, 72.2% for physical activity, 42.3% for screen time, and 63.9% for sleep duration. Also, according to the 2021 National Survey on Drug Use and Health (NSDUH), 29.5 million people ages 12 and older had an Alcohol Use Disorder (AUD) in the year 2020. Several other factors, such as rising genetic disorders are leading drivers of the liquid embolic system globally. Apart from this, accelerated diagnostic tests with advanced therapeutics have resulted in faster treatment procedures and better accuracy which is also driving this market of liquid embolic system at a steady rate. These days companies are trying to deliver environment-friendly products. For instance, Medtronic's Onyx 34L LES packaging with 6 ml vials has been made with 98% recyclable content which makes it environment friendly.

Based on type, the market is segmented into liquid embolic vials and liquid embolic prefilled injectables. The liquid embolic vials segment held the maximum share in the global market of liquid embolic system market in 2022. This segment dominated the market because of the feasibility of using the product for large-volume treatments. The ease of use of using less storage space is also a propelling factor for this segment. Thus, liquid embolic vials held a significant share of the market amongst blade types in 2022.

Based on indication, the market is categorized into brain arteriovenous malformations, tumor and brain cancer, brain aneurysm, and others. The brain arteriovenous malformations segment is expected to hold a significant share of the market in the forecast period owing to rising cases of brain arteriovenous malformations and genetic abnormalities. For instance, according to the Brain Aneurysm Foundation, in about 5-10% of individuals, arteriovenous malformations are discovered during a routine examination while in approximately half of the patients, an arteriovenous malformation makes its presence known with sudden hemorrhage or stroke. Thus, the brain arteriovenous malformations category is expected to witness a higher CAGR during the forecast period.

Based on end-users, the market is segmented into hospitals, ambulatory surgical centers, and others. The hospitals category held the highest share in the market in 2022 attributed to the ease of access to healthcare provided by hospitals, the availability of highly qualified healthcare personnel, the utilization of advanced medical technology, and a diverse number of units all over the globe. For instance, according to the American Hospital Association in 2023, there are in total of 6,129 hospitals in the U.S with 919,649 staffed beds and 34,011,386 hospital admissions in the year 2022. The market for the hospital segment is highly competitive and is projected to remain so in the foreseeable future. Thus, the hospital segment held dominance in the market in the year 2022.

For a better understanding of the market adoption of liquid embolic system, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is expected to grow with a high CAGR in the global liquid embolic system market in the forecast period. Several factors such as the development of a wide range of medical products, enhanced accessibility, increasing cases of chronic diseases, and diversified healthcare costs are driving the market's growth during the forecast period. For instance, according to the National Institute of Health in 2022, there were approximately 4,820,000 and 2,370,000 new cancer cases in China. Further, the presence of key medical device companies in the region, and the surge in government initiatives and special communities are also having a positive impact on the market's growth. There have been significant improvisations and enhancements in women's health diagnostics in the region. Thus, amongst regions, APAC is expected to witness higher CAGR during the forecast period.

Some of the major players operating in the market include: Medtronic; Terumo Corporation; BALT group; Johnson & Johnson Services, Inc.; Meril Life Sciences Pvt. Ltd.; Fluidx Medical Technology, Inc.; Instylla, Inc.; TheraTarget; Sirtex SIR-Spheres Pty Ltd.; NeuroSafe Medical Co., Ltd.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Liquid Embolic System Market
• 2.2. Research Methodology of the Liquid Embolic System Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE LIQUID EMBOLIC SYSTEM MARKET

6 LIQUID EMBOLIC SYSTEM MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY TYPE

• 7.1. Liquid Embolic Vials
• 7.2. Liquid Embolic Prefilled Injectables

8 MARKET INSIGHTS BY INDICATION

• 8.1. Brain Arteriovenous Malformations
• 8.2. Tumor and Brain Cancer
• 8.3. Brain Aneurysm
• 8.4. Others

9 MARKET INSIGHTS BY END USER

• 9.1. Hospitals
• 9.2. Ambulatory Surgical Centers
• 9.3. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 LIQUID EMBOLIC SYSTEM MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 LIQUID EMBOLIC SYSTEM MARKET OPPORTUNITIES

13 LIQUID EMBOLIC SYSTEM MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1. Medtronic
• 17.2. Terumo Corporation
• 17.3. BALT group
• 17.4. Johnson & Johnson Services, Inc.
• 17.5. Meril Life Sciences Pvt. Ltd.
• 17.6. Fluidx Medical Technology, Inc.
• 17.7. Instylla, Inc.
• 17.8. TheraTarget
• 17.9. Sirtex SIR-Spheres Pty Ltd.
• 17.10. NeuroSafe Medical Co., Ltd.

18 DISCLAIMER